TNFSF13B and airway hyperresponsiveness: GBFXD inhibits the expression of B cell activating factor (BAFF) secreted by pulmonary macrophages and its related receptors, reduces the activation of B cells and the release of immunoglobulin E (IgE) (Liang et al., 2020a), inhibits the polarization activation of M2 macrophages, improves Th1/Th2 balance, reduces airway hyperresponsiveness and mucus secretion (Liu et al., 2019), regulates cholesterol transport, activates complement factors, and improves respiratory function and virus-induced asthma (Xing et al., 2019).